
Hims & Hers Health Stock Slides Friday: What's Going On?
Track HIMS's AI-powered predictions, market trends, and investment insights.
You don't hold HIMS in your mock portfolio yet.
Upgrade to see the full Evidence Stack
What Changed, Why Now, and Risk Flags — available on the Investor plan and above
Get StartedThe negative EPS of -0.09 and an effectively meaningless, deeply negative PE ratio of -291 indicate that hims is still unprofitable on a GAAP earnings basis. While the market may be pricing in growth and potential operating leverage, current reported profitability remains weak. Without evidence of a clear and near-term path to sustained positive earnings, the financial profile skews more risky than not.
At $26.19, hims is trading about 4.6% higher over the last month, indicating some short-term positive momentum. However, the stock is well below its 200-day moving average of $34.14, which is a classic sign of a longer-term downtrend or overhead resistance. The combination suggests a weak intermediate technical setup despite a modest recent bounce.
Alternative data for hims is mixed but generally stable to modestly positive. Web traffic at an estimated 172,083 visitors per month and 63 job openings (down 8.7% month over month) suggest a business that is active but perhaps moderating its growth or hiring pace. Social media followings across Instagram, Facebook, and LinkedIn are growing slowly, indicating steady brand awareness but not explosive consumer traction.
Overall, hims presents a mixed picture: the company remains unprofitable with a very high implied valuation multiple, and the stock trades below its 200-day moving average despite a recent price uptick. Alternative data show steady but not explosive engagement and a slight pullback in hiring, consistent with a company balancing growth and cost discipline. Taken together, the signals lean toward a neutral stance, with meaningful execution risk but also embedded growth expectations already reflected in the stock.
Our AI Score rates companies on a scale from 0 to 10, based on alternative data points such as web traffic, app downloads, and job postings — combined with financial health indicators and technical signals.

Hims & Hers Health Stock Slides Friday: What's Going On?



Hims & Hers Names Dr. Anant Vinjamoori as Chief Medical Officer of Hims
Hims & Hers Health (HIMS) is trading at $26.15 on the NYSE, posting a single-day gain of 3.0% with unusually elevated volume of over 20.6 million shares. The $5.8 billion market cap telehealth platform operates across sexual health, skincare, hair care, and wellness verticals, delivering both prescription and over-the-counter products through its direct-to-consumer digital platform. The elevated volume today stands out as a key data point — heavy turnover relative to normal activity can signal either institutional repositioning or retail-driven momentum, and warrants close monitoring for follow-through in the sessions ahead.
TrendEdge's AI model assigns HIMS a score of 5 out of 10 — a neutral reading that reflects a mixed signal environment. Key drivers flagged in the AI evidence include a recent Reddit activity spike of 100 mentions in a 24-hour window, though this figure sits 36% below the 7-day average, suggesting the social buzz is fading rather than building. Volume is running at approximately 0.5 times the average, which the model flags as a crowd spike risk. The combination of a short-term price move, declining social momentum, and subdued relative volume produces a cautious, non-committal score rather than a clear directional thesis.
Looking ahead, investors should watch whether today's 3.0% price gain sustains with conviction or fades as Reddit activity cools. With 61 active job postings, Hims & Hers appears operationally active, which could signal ongoing product or market expansion. Key risks include regulatory pressure on telehealth prescribing practices and competitive pricing dynamics in the GLP-1 and men's health categories. The AI score of 5/10 suggests holding off on high-conviction positioning until stronger directional signals emerge across volume, sentiment, and price action.
Unlock comprehensive alternative data signals to make better investment decisions
TrendEdge provides tools and data for research and educational purposes only and does not provide investment advice or personal recommendations.
Web Traffic
203,140
Twitter Followers
31,842
Instagram Followers
256,418
LinkedIn Followers
229,081
Job Postings
69
LinkedIn Employees
2,048
News Mentions
0
Key Metrics